{
    "Trade/Device Name(s)": [
        "Quest Diagnostics Urine Cocaine Metabolite EIA"
    ],
    "Submitter Information": "Quest Diagnostics",
    "510(k) Number": "K062929",
    "Predicate Device Reference 510(k) Number(s)": [
        "K023281"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DIO"
    ],
    "Summary Letter Date": "September 28, 2006",
    "Summary Letter Received Date": "September 28, 2006",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.3250"
    ],
    "Regulation Name(s)": [
        "Cocaine and cocaine metabolite test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Benzoylecgonine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)",
        "Competitive homogeneous assay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Quest Diagnostics Urine Cocaine Metabolite EIA, a competitive enzyme immunoassay for qualitative screening of benzoylecgonine in urine.",
    "Indications for Use Summary": "Qualitative detection of benzoylecgonine, the primary metabolite of cocaine, in human urine on automated clinical chemistry analyzers for laboratory in vitro diagnostic use.",
    "fda_folder": "Toxicology"
}